PURPOSE:Adolescents (age 15 to 21 years) compared with younger children with mature B-cell non-Hodgkin's lymphoma (NHL) have been historically considered to have an inferior prognosis. We therefore analyzed the impact of age and other diagnostic factors on the risk of treatment failure in children and adolescents treated on the French-American-British Mature B-Cell Lymphoma 96 (FAB LMB 96) trial. PATIENTS AND METHODS: Patients were divided by risk: group A (limited), group B (intermediate), and group C (advanced), as previously described. Prognostic factors analyzed for event-free survival (EFS) included age (< 15 v ≥ 15 years), stage (I/II v III/IV), primary site, lactate dehydrogenase (LDH), bone marrow/CNS (BM/CNS) involvement, and histology (diffuse large B-cell lymphoma v mediastinal B-cell lymphoma v Burkitt lymphoma or Burkitt-like lymphoma). RESULTS: The 3-year EFS for the whole cohort was 88% ± 1%. Age was not associated as a risk factor for increased treatment failure in either univariate analysis (P = .15) or multivariate analysis (P = .58). Increased LDH (≥ 2 × upper limit of normal [ULN] v < 2 × ULN), primary site, and BM-positive/CNS-positive disease were all independent risk factors associated with a significant increase in treatment failure rate (relative risk, 2.0; P < .001, P < .012, and P < .001, respectively). CONCLUSION:LDH level at diagnosis, mediastinal disease, and combined BM-positive/CNS-positive involvement are independent risk factors in children with mature B-cell NHL. Future studies should be developed to identify specific therapeutic strategies (immunotherapy) to overcome these risk factors and to identify the biologic basis associated with these prognostic factors in children with mature B-cell NHL.
RCT Entities:
PURPOSE: Adolescents (age 15 to 21 years) compared with younger children with mature B-cell non-Hodgkin's lymphoma (NHL) have been historically considered to have an inferior prognosis. We therefore analyzed the impact of age and other diagnostic factors on the risk of treatment failure in children and adolescents treated on the French-American-British Mature B-Cell Lymphoma 96 (FAB LMB 96) trial. PATIENTS AND METHODS: Patients were divided by risk: group A (limited), group B (intermediate), and group C (advanced), as previously described. Prognostic factors analyzed for event-free survival (EFS) included age (< 15 v ≥ 15 years), stage (I/II v III/IV), primary site, lactate dehydrogenase (LDH), bone marrow/CNS (BM/CNS) involvement, and histology (diffuse large B-cell lymphoma v mediastinal B-cell lymphoma v Burkitt lymphoma or Burkitt-like lymphoma). RESULTS: The 3-year EFS for the whole cohort was 88% ± 1%. Age was not associated as a risk factor for increased treatment failure in either univariate analysis (P = .15) or multivariate analysis (P = .58). Increased LDH (≥ 2 × upper limit of normal [ULN] v < 2 × ULN), primary site, and BM-positive/CNS-positive disease were all independent risk factors associated with a significant increase in treatment failure rate (relative risk, 2.0; P < .001, P < .012, and P < .001, respectively). CONCLUSION: LDH level at diagnosis, mediastinal disease, and combined BM-positive/CNS-positive involvement are independent risk factors in children with mature B-cell NHL. Future studies should be developed to identify specific therapeutic strategies (immunotherapy) to overcome these risk factors and to identify the biologic basis associated with these prognostic factors in children with mature B-cell NHL.
Authors: A Reiter; M Schrappe; M Tiemann; W D Ludwig; E Yakisan; M Zimmermann; G Mann; A Chott; W Ebell; T Klingebiel; N Graf; B Kremens; S Müller-Weihrich; H J Plüss; F Zintl; G Henze; H Riehm Journal: Blood Date: 1999-11-15 Impact factor: 22.113
Authors: C Patte; A Auperin; J Michon; H Behrendt; G Leverger; D Frappaz; P Lutz; C Coze; Y Perel; M Raphaël; M J Terrier-Lacombe Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: Mitchell S Cairo; Richard Sposto; Sherrie L Perkins; Anna T Meadows; Margo L Hoover-Regan; James R Anderson; Stuart E Siegel; Mark A Lones; Nicole Tedeschi-Blok; Marshall E Kadin; Carl R Kjeldsberg; John F Wilson; Warren Sanger; Erin Morris; Mark D Krailo; Jonathan L Finlay Journal: Br J Haematol Date: 2003-02 Impact factor: 6.998
Authors: M A Lones; S L Perkins; R Sposto; M E Kadin; C R Kjeldsberg; J F Wilson; M S Cairo Journal: J Clin Oncol Date: 2000-11-15 Impact factor: 44.544
Authors: M S Cairo; M D Krailo; M Morse; R J Hutchinson; R E Harris; C R Kjeldsberg; M E Kadin; E Radel; L J Steinherz; E Morris; J L Finlay; A T Meadows Journal: Leukemia Date: 2002-04 Impact factor: 11.528
Authors: Andrea Meinhardt; Birgit Burkhardt; Martin Zimmermann; Arndt Borkhardt; Udo Kontny; Thomas Klingebiel; Frank Berthold; Gritta Janka-Schaub; Christoph Klein; Edita Kabickova; Wolfram Klapper; Andishe Attarbaschi; Martin Schrappe; Alfred Reiter Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Kerry J Savage; Stefano Monti; Jeffery L Kutok; Giorgio Cattoretti; Donna Neuberg; Laurence De Leval; Paul Kurtin; Paola Dal Cin; Christine Ladd; Friedrich Feuerhake; Ricardo C T Aguiar; Sigui Li; Gilles Salles; Francoise Berger; Wen Jing; Geraldine S Pinkus; Thomas Habermann; Riccardo Dalla-Favera; Nancy Lee Harris; Jon C Aster; Todd R Golub; Margaret A Shipp Journal: Blood Date: 2003-08-21 Impact factor: 22.113
Authors: Mitchell S Cairo; Richard Sposto; Margo Hoover-Regan; Anna T Meadows; James R Anderson; Stuart E Siegel; Marshall E Kadin; Carl R Kjeldsberg; John F Wilson; Sherrie L Perkins; Mark A Lones; Erin Morris; Jonathan L Finlay Journal: Am J Hematol Date: 2003-01 Impact factor: 10.047
Authors: Andreas Rosenwald; George Wright; Karen Leroy; Xin Yu; Philippe Gaulard; Randy D Gascoyne; Wing C Chan; Tong Zhao; Corinne Haioun; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Elias Campo; Emili Montserrat; Armando Lopez-Guillermo; German Ott; H Konrad Muller-Hermelink; Joseph M Connors; Rita Braziel; Thomas M Grogan; Richard I Fisher; Thomas P Miller; Michael LeBlanc; Michael Chiorazzi; Hong Zhao; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Louis M Staudt Journal: J Exp Med Date: 2003-09-15 Impact factor: 14.307
Authors: Matthew J Barth; Stanton Goldman; Lynette Smith; Sherrie Perkins; Bruce Shiramizu; Thomas G Gross; Lauren Harrison; Warren Sanger; Mark B Geyer; Lisa Giulino-Roth; Mitchell S Cairo Journal: Br J Haematol Date: 2013-06-27 Impact factor: 6.998
Authors: Sanghoon Lee; Nancy S Day; Rodney R Miles; Sherrie L Perkins; Megan S Lim; Janet Ayello; Carmella van de Ven; Lauren Harrison; Nader K El-Mallawany; Stanton Goldman; Mitchell S Cairo Journal: Br J Haematol Date: 2017-05-04 Impact factor: 6.998
Authors: J Kimble Frazer; Kevin J Li; Paul J Galardy; Sherrie L Perkins; Anne Auperin; James R Anderson; Ross Pinkerton; Allen Buxton; Thomas G Gross; Jean Michon; Guy Leverger; Howard J Weinstein; Lauren Harrison; Bruce Shiramizu; Mathew J Barth; Stanton C Goldman; Catherine Patte; Mitchell S Cairo Journal: Br J Haematol Date: 2018-08-16 Impact factor: 6.998
Authors: Stanton Goldman; Lynette Smith; Paul Galardy; Sherrie L Perkins; John Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Bruce Shiramizu; Matthew Barth; Mitchell S Cairo Journal: Br J Haematol Date: 2014-07-26 Impact factor: 6.998
Authors: Bruce Shiramizu; Stanton Goldman; Lynette Smith; Melissa Agsalda-Garcia; Paul Galardy; Sherrie L Perkins; J Kimble Frazer; Warren Sanger; James R Anderson; Thomas G Gross; Howard Weinstein; Lauren Harrison; Matthew J Barth; Lara Mussolin; Mitchell S Cairo Journal: Br J Haematol Date: 2015-04-08 Impact factor: 6.998
Authors: P Satwani; Z Jin; P L Martin; M Bhatia; J H Garvin; D George; S Chaudhury; J Talano; E Morris; L Harrison; J Sosna; M Peterson; O Militano; S Foley; J Kurtzberg; M S Cairo Journal: Leukemia Date: 2014-06-18 Impact factor: 11.528